Article

Q-factor optimization appears to enhance outcomes of wavefront-guided LASIK

Outcomes after wavefront-guided LASIK for myopia and myopic astigmatism using two Q-factor optimized excimer laser systems (NAVEX, Nidek; Zyoptix, Bausch & Lomb) were compared in a retrospective study.

Key Points

The comparative study included 40 eyes of 22 patients in each group that were followed for at least 6 months after treatment for myopia or myopic astigmatism between January and November 2004. Based on previous results achieved using each system for conventional LASIK, the NAVEX treatment was performed with a 4.5-mm optical zone and 8.0-mm ablation zone. The optical zone and ablation zone sizes for the Zyoptix treatment were 6.0 mm and 8.0 to 8.3 mm, respectively. The NAVEX treatment was performed using algorithm software (OPDCAT, Nidek) that applies the wavefront-guided ablation while aiming to maintain corneal asphericity.

Q-factor optimization

The two study groups in the retrospective trial were matched with respect to age (about 34 years) and preoperative values for best spectacle-corrected visual acuity (20/20), sphere (about –4.3 D), cylinder (about –0.8 D), and SE (about –4.7 D). The target refraction for all eyes was plano, and the same keratome system (MK-2000, Nidek) was used for all flaps.

At 6 months, uncorrected visual acuity (UCVA) was 20/10 or better in 10% of eyes treated with the Zyoptix system but in none of the NAVEX-treated eyes. Eighty-six percent of eyes in the NAVEX group achieved UCVA of 20/12.5 or better, however, compared with only 59% of Zyoptix-treated eyes. Nevertheless, no significant difference in UCVA was observed between groups at 6 months.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.